Given the selective upregulation of MYO1F in activated microglia in the context of neurodegenerative disorders, MYO1F warrants further investigation as a pharmacological target for regulating microglial activation and attenuating neuroinflammation in conditions such as AD or FTD/ALS. This evidence concerns the gene MYO1F and Alzheimer disease.